INTRODUCTION

Neuro-metabolic disorders are caused by both neuronal and metabolic system involvement. The type and extent of evaluation for the chronic forms of these disorders depends on demographic information, including sex, age, underlying disorders, family history, and specific signs and symptoms. Neuro-metabolic disorders, often caused by defects in enzymatic functions, are classified in different subgroups. Patients with neuro-metabolic disorders might present with seizures, aciduria, developmental delays, and/or ophthalmological abnormalities. Progressive external ophthalmoplegia has been mentioned as one of the symptoms in mitochondrial disorders.
Pigmentary degeneration of the retina may be observed in Hallervorden–Spatz syndrome.\(^1\) Corneal clouding is a common manifestation in Hurler’s syndrome.\(^1\) Retinitis pigmentosa and cataracts are the signs of Refsum disease.\(^1\) Corneal clouding and cherry-red macula are among the most common clinical symptoms of GM1 gangliosidosis reported in 60% of these patients.\(^2\) Optic nerve atrophy is one of the clinical features of Canavan disorder.\(^4\) In this study, we present neuro-opthalmologic findings of all neuro-metabolic cases referred to the Pediatric Neurology Research Center of Mofid Children’s Hospital, Tehran, Iran, within a 10-year period.

**METHODS**

This retrospective study was performed on patients who were diagnosed with neuro-metabolic disorders in the Neurology Department of Mofid Children’s Hospital in Tehran, Iran, between March 2004 and May 2014. The diagnosis was based on clinical manifestations, neuroimaging findings, and laboratory assessments in a reference lab in Germany (Wagner Stibble laboratory, Hanover, Germany). Data including age, sex, past medical history, developmental status, general appearance, and clinical and neuroimaging findings were collected.

Diagnostic criteria of neuro-metabolic disorders were classified based on the type of disorder, such as enzymatic assessments for biotinidase deficiency, Sandhoff and Tay–Sachs diseases, metachromatic leukodystrophy (MLD), and galactosemia; acil carnitine profile assessment for lipid oxidation disorders; serum acil carnitine profile assessment and urine organic acid evaluation for organic acidemia; very long-chain fatty acid (VLCFA) assessment for paroxysmal disorders; genetic assessment for Pelizaeus–Merzbacher disease (PMD), PMD-like diseases, and neuronal ceroid lipofuscinosis (NCL). All patients underwent ophthalmological examination. Refraction was performed for all patients and if the patient’s condition was appropriate (mental status, cooperation, age), the best corrected visual acuity (BCVA) was documented. Abnormal ocular motilities, strabismus, nystagmus, abnormal head tilts and face turns, and eyelids abnormalities such as ptosis, were also documented. Anterior segments (cornea, anterior chamber, lens, and anterior vitreous body) were examined using slit lamp biomicroscopy, and fully dilated fundus examination using indirect ophthalmoscopy and slit lamp biomicroscopy was also performed in all patients to assess their retinas, vitreous bodies, and optic nerves. Institutional ethical approval for the conduct of this study was obtained from the Pediatric Neurology Research Center of Shahid Beheshti University of Medical Sciences, Tehran, Iran. All parents signed a written consent form for participation in the study. Data in this study were analyzed using SPSS software version 18. (SPSS Inc., Chicago, IL, USA).

**RESULTS**

A total of 213 patients with 34 different disorders were included. They were classified into 7 subgroups: 1) organic acidemia and aminoacidopathy, 2) lipid oxidation disorders, 3) storage diseases, 4) urea cycle disorders, 5) progressive myoclonic epilepsy, 6) paroxysmal disorders, and 7) leukodystrophy. The findings for the evaluated patients are summarized in Table 1. Among these patients, 45.7% were female and 54.3% were male. The average age of the patients at the time of diagnosis was 41 months. Of all patients, 71.4% were offspring of consanguineous marriages (57.4% of them were second-degree and 14% were third-degree); 23.5% of patients also presented a positive family history of similar diseases.

During developmental assessment, only 13% of patients exhibited normal development; 47.5% of patients showed developmental delay; 21% demonstrated developmental delay and regression; 18.5% of them presented with developmental regression.

Seventy-two patients of the total 213 patients exhibited ophthalmological abnormalities, including 34 cases with blurred vision. Ophthalmologic findings from external examination included ptosis (1 patient), nystagmus (8 patients), strabismus (11 patients), vertical gaze palsy (4 patients), and lack of fixation (12 patients). Cataracts (4 patients), Kayser–Fleischer ring (1 patient), and lens dislocation (3 patients) were the pathologic findings from anterior segment examinations. In funduscopic and posterior segment evaluation, pathologic findings included cherry-red spots (23 patients, including 18 patients with GM2 gangliosidosis disease), optic atrophy (4 patients), retinitis pigmentosa (2 patients with Zellweger syndrome), and ocular albinism (1 patient).

Ophthalmological abnormalities were observed in 33.5% of patients with the following distributions: 17.2% of cases with amino acidopathy; 78.4% of cases with storage disorders; 33.3% of cases with urea cycle disorders; 55.6% of cases with paroxysmal disorders; 9% of cases with fatty acid oxidation defects; 44.4% of cases with leukodystrophy; and 25% of cases with progressive myoclonic epilepsy [Table 2].

**DISCUSSION**

Ophthalmological evaluation is warranted in patients with suspected neuro-metabolic disorders. One-third of our patients exhibited ophthalmological involvement. Some neuro-metabolic disorders have specific ophthalmic involvements that are important for diagnosis, such as blurred vision due to optic atrophy in patients with biotinidase deficiency. Biotinidase deficiency is
Neuro-metabolic Disorders; Jafari et al

Table 1. Summary of findings in evaluated patients

| Gender                  | Male: 54.3% | Female: 55.7% |
|-------------------------|-------------|---------------|
| Age (month)             | 41±46.1     | Min: 0.5 Max: 276 |
| Consanguinity of marriage | Positive: 71.4% | Negative: 28.6% |
| Family history of same disease | Positive: 23.5% | Negative: 76.5% |
| Developmental status    | Abnormal: 87% | Normal: 13% |
| Ophthalmologic problem | Positive: 32.9% (loss of vision; strabismus; nystagmus; retinitis pigmentosa; lack of fixation; Kayser–Fleischer ring; blurred vision; optic atrophy; lens dislocation; secondary cataract and cherry red spot) | Normal: 67.1% |

Convulsion: Positive: 55.5% | Normal: 45.5%
EEG Findings: Abnormal: 20.8% | Normal: 79.2%
Brain MRI findings: Abnormal: 64% | Normal: 36%

Min, minimum; Max, maximum; SD, standard deviation; EEG, electroencephalography; MRI, magnetic resonance imaging

Table 2. Ophthalmologic findings in evaluated cases with neuro‑metabolic disorders

| Neuro-metabolic disorders       | Ophthalmologic abnormalities                                                                 | Percentage per disorders |
|--------------------------------|---------------------------------------------------------------------------------------------|--------------------------|
| Amino Acidopathy (58 patients) | Strabismus (3 patients, 5.17%) Nystagmus (2 patients, 3.44%) Ocular dislocation (3 patients, 5.17%) Ocular albinism (1 patient, 1.72%) Blurred vision (8 patients, 13.79%) | 17.2%                    |
| Storage disorders (36 patients) | Lack of fixation (4 patients, 11.11%) Blurred vision (9 patients, 25%) Strabismus (4 patients, 11.11%) Nystagmus (3 patients, 8.33%) Cherry red spot (16 patients, 44.44%) Cataract (4 patients, 11.11%) | 78.4%                    |
| Urea Cycle disorders (12 patients) | Strabismus (4 patients, 33.33%) Nystagmus (3 patients, 25%) | 33.3%                    |
| Paroxysmal disorders (11 patients) | Blurred vision (6 patients, 54.54%) Optic atrophy (4 patients, 36.36%) | 55.6%                    |
| Fatty Acid Oxidation defect (34 patients) | Secondary cataract (1 patients, 2.9%) Blurred vision (5 patients, 14.70%) | 9%                      |
| Leukodystrophy (30 patients) | Retinitis pigmentosa (2 patients, 6.66%) Lack of fixation (8 patients, 22.22%) Cherry red spot (7 patients, 23.33%) | 44.4%                    |
| Progressive Myoclonic Epilepsia (32 patients) | Vertical gaze palsy (4 patients, 12.5%) Blurred vision (6 patients, 18.75%) | 25%                      |

Birth defects, Biochemistry and Genetics, Cataracts, Glaucoma, Magnetic resonance imaging, Ophthalmology, Retinitis pigmentosa, Visual Loss, Wilson’s disease.
adrenoleukodystrophy (ALD). In this study, 35% of patients with Canavan disease exhibited blurred vision and optic atrophy.

Homocystinuria is an autosomal recessive disorder that is caused by a deficiency in cystathionine-beta-synthetase. Ophthalmic complications include optic atrophy, secondary glaucoma, cataracts, and retinal detachment. In this study, 35% of patients with homocysteinuria exhibited lens dislocation and secondary cataracts.

GM2 gangliosidosis is classified into two groups: Sandhoff disease, which may present with developmental regression within the first 6 months of life, and Tay–Sachs disease, which is caused by an accumulation of gangliosides in the retina and brain. Patients with GM2 gangliosidosis may develop cherry-red spots due to an accumulation of GM2 gangliosides in the ganglion cells of the retina, resulting in retinal posterior pole thickness and loss of transparency.

In the current study, 90% of patients with GM2 gangliosidosis (Sandhoff and Tay–Sachs diseases) exhibited cherry-red spots.

In this study, 66% of patients with Niemann–Pick type C disease exhibited vertical gaze palsy. Abnormal vertical optokinetic nystagmus may be observed in patients with Niemann–Pick type C disease. All patients with NCL presented with optic atrophy in this study. This disorder is very important to consider for ophthalmological examination. NCL may present with a dramatic loss of vision, blindness, or optic atrophy. Furthermore, 75% of patients with Chiari malformation type 1 (CM1) disease exhibited optic atrophy.

In conclusion, we suggest that the diagnosis of neuro-metabolic disorders may be facilitated by the detection of ophthalmologic abnormalities. This would allow for early intervention and enhance prenatal diagnosis of the disease in future offspring. Early diagnosis can help us in preventing and inhibiting the progression of signs and symptoms in selected neuro-metabolic disorders through appropriate treatment. We suggest conducting ophthalmic examinations in all patients suspected to harbor neuro-metabolic disorders.

**Financial Support and Sponsorship**

Nil.

**Conflicts of Interest**

There are no conflicts of interest.

**REFERENCES**

1. Boltshauser E, Spycher MA. [Diagnostic procedure in neurodegenerative diseases with a chronic course]. Klin Padiatr 1986;198:79-83.

2. Karimzadeh P, Ahmadabadi F, Jafari N, Jabbehdari S, Alaee MR, Ghofrani M, et al. Biotinidase deficiency: A reversible neurometabolic disorder (an Iranian pediatric case series). Iran J Child Neurol 2013;7:47-52.

3. Karimzadeh P, Jafari N, Ahmad Abadi F, Jabbehdari S, Taghdiri MM, Nemati H, et al. Methylmalonic acidemia: Diagnosis and neuroimaging findings of this neurometabolic disorder (an Iranian pediatric case series). Iran J Child Neurol 2013;7:63-6.

4. Moser HW. Neurometabolic disease. Curr Opin Neurol 1998;11:91-95.

5. Karimzadeh P, Jafari N, Nejad Biglari H, Jabbeh Dari S, Ahmad Abadi F, Alaee MR, et al. GM2-Gangliosidosis (Sandhoff and Tay Sachs disease): Diagnosis and Neuroimaging Findings (An Iranian Pediatric Case Series). Iran J Child Neurol 2014;8:55-60.

6. Kyllerman M, Mansson JE, Lichtenstein M, Percy AK, Nordborg C. Distal infantile neuroaxonal dystrophy—a new familial variant with perineuronal argyrophilic bodies. Acta Neuropathol 2001;102:83-88.

7. Alrifai MT, AlShaya MA, Abulaban A, Alfadhel M. Hereditary neurometabolic causes of infantile spasms in 80 children presenting to a tertiary care center. Pediatr Neurol 2014;51:390-397.

8. Dotti MT, Rafa A, Federico A. Cerebrotendinous xanthomatosis: Heterogeneity of clinical phenotype with evidence of previously underscribed ophthalmological findings. J Inherit Metab Dis 2001;24:696-706.

9. Moraes CT, DiMauro S, Zeviani M, Lombes A, Shanske S, Miranda AF, et al. Mitochondrial DNA Deletions in Progressive External Ophthalmoplegia and Kearns-Sayre Syndrome. N Engl J Med 1989;320:1293-1299.

10. Hayflick SJ, Westaway SK, Levinson B, Zhou B, Johnson MA, Ching KH, et al. Genetic, Clinical, and Radiographic Delineation of Hallervorden–Spatz Syndrome. N Engl J Med 2003;348:33-34.

11. Staba S, Loeblar ML, Poe M, Kim Y, Martin PL, Szabolcs P, et al. Card-Blood Transplants from Unrelated Donors in Patients with Hurler’s Syndrome. N Engl J Med 2004;350:1960-1969.

12. Claridge KG, Gibberd FB, Sidye MC. Refsum disease: The presentation and ophthalmic aspects of Refsum disease in a series of 23 patients. Eye 1992;6:371-375.

13. Nicola B, Fernando S. GM gangliosidosis: Review of clinical, molecular, and therapeutic aspects. Mol Genet Metab 2008;94:391-396.

14. Kumar S, Mattan NS, de Vellis J. Canavan disease: A white matter disorder. Ment Retard Dev Disabil Res Rev 2006;12:157-165.

15. Haines SR, Longmuir RA. Optic neuropathy due to biotinidase deficiency in a 19-year-old man. JAMA Ophthalmol 2014;132:228-230.

16. Hayati AA, Wan-Hitam WH, Cheong MT, Yunus R, Shahirah I. Optic neuritis in a child with biotinidase deficiency: Case report and literature review. Clin Ophthalmol 2012;6:389-395.

17. Rahman S, Standing S, Dalton RN, Pike MG. Late presentation of biotinidase deficiency with acute visual loss and gait disturbance. Dev Med Child Neurol 1997;39:830-831.

18. Ramaekers VT, Suormala TM, Brab M, Duran R, Heimann G, Baumgartner ER. A biotinidase Km variant causing late onset bilateral optic neuropathy. Arch Dis Child 1992;67:115-119.

19. Salbert BA, Astruc J, Wolf B. Ophthalmologic findings in biotinidase deficiency. Ophthalmologica 1993;206:177-181.

20. Hieber S, Masuda T, Hacia JG, Moser AB, Faust PL, Liu A, et al. The Plex G444D mouse: A model for mild human Zellweger spectrum disorder. Mol Genet Metab 2014;111:522-532.

21. Al-Hazzaa SA, Ozand PT. Peroxisomal bifunctional enzyme deficiency with associated retinal findings. Ophthalmic Genet 1997;18:93-99.

22. Sheline CT. Thiamine supplementation attenuated hepatocellular carcinoma in the Atp7b mouse model of Wilson’s disease. Anticancer Res 2011;31:3395-3399.

23. Jang HJ, Kim JM, Choi CY. Elemental analysis of sunflower cataract in Wilson’s disease: A study using scanning transmission electron microscopy and energy dispersive spectroscopy. Exp Eye Res 2014;121:58-65.
24. Li X, Ye T, Li Y, Zhang X. Secondary glaucoma with copper deposition in trabecular meshwork in Wilson disease. *Clin Experiment Ophthalmol* 2014;42:204-205.

25. Huo LJ, Liao RD, Chen XM. [Ophthalmic manifestations of Wilson’s disease]. *Zhonghua Yan Ke Za Zhi* 2008;44:128-130.

26. Trobe JD, Sharpe JA, Hirsh DK, Gebarski SS. Nystagmus of Pelizaeus-Merzbacher disease. A magnetic search-coil study. *Arch Neurol* 1991;48:87-91.

27. Burke JP, O’Keefe M, Bowell R, Naughten ER. Ocular complications in homocystinuria–early and late treated. *Br J Ophthalmol* 1989;73:427-431.

28. Ghosh M, Hunter WS, Wedge C. Corneal changes in Tay-Sachs disease. *Can J Ophthalmol* 1990;25:190-192.

29. Tay SK, Low PS, Ong HT, Loke KY. Sandhoff disease—a case report of 3 siblings and a review of potential therapies. *Ann Acad Med Singapore* 2000;29:514-517.

30. Chan LY, Balasubramaniam S, Sudder R, Jamalia R, Karunakar TV, Alagaratnam J. Tay-Sach disease with “cherry-red spot”—first reported case in Malaysia. *Med J Malaysia* 2011;66:497-498.

31. Garbutt S, Harris CM. Abnormal vertical optokinetic nystagmus in infants and children. *Br J Ophthalmol* 2000;84:451-455.

32. Seeliger M, Ruther K, Apfelstedt-Sylla E, Schlote W, Wohlrab M, Zrenner E. [Juvenile neuronal ceroid lipofuscinosis (Batten-Mayou) disease. Ophthalmologic diagnosis and findings]. *Ophthalmologe* 1997;94:557-562.